Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity

Expert Opin Drug Saf. 2019 Jul;18(7):549-552. doi: 10.1080/14740338.2019.1618268. Epub 2019 May 17.

Author

Nicholas T Bello^{1

2}

Affiliations

¹ a Department of Animal Sciences , Rutgers, The State University of New Jersey , New Brunswick , NJ , USA.
² b New Jersey Institute for Food, Nutrition, and Health , Rutgers, The State University of New Jersey , New Brunswick , NJ , USA.

PMID: 31092063
DOI: 10.1080/14740338.2019.1618268

No abstract available

Keywords: Bupropion; contrave; naltrexone; obesity; opioid resistant analgesia; psoriasis.

Publication types

Editorial

MeSH terms

Anti-Obesity Agents / administration & dosage
Anti-Obesity Agents / adverse effects*
Bupropion / administration & dosage
Bupropion / adverse effects*
Delayed-Action Preparations
Drug Combinations
Humans
Naltrexone / administration & dosage
Naltrexone / adverse effects*
Obesity / drug therapy*

Substances

Anti-Obesity Agents
Delayed-Action Preparations
Drug Combinations
bupropion hydrochloride, naltrexone hydrochoride drug combination
Bupropion
Naltrexone